Angeline Prabhu
Infectious Disease · Las Vegas, NVNPI 1245645878
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,754 of the $4,212 with a category attached, or 89.1%. 18 manufacturers reported payments, led by Viiv Healthcare Company at 26.3% of the total. Reporting peaked in 2023 at $1,677 and has fallen 69.5% since, to $511 in 2025.
Across 152 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Merck$777
- Gilead$654
- Astellas Pharma US Inc$499
- Shionogi Inc$204
- Ferring Pharmaceuticals Inc.$182
- plus $789 from 12 others
What the payments were for
- Food & beverage$3,75489%
- Education$45811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 55 | $1,108 |
| Merck | 33 | $777 |
| Gilead | 19 | $654 |
| Astellas Pharma US Inc | 10 | $499 |
| Shionogi Inc | 5 | $204 |
| Ferring Pharmaceuticals Inc. | 4 | $182 |
| La Jolla Pharmaceutical Company | 4 | $166 |
| Paratek Pharmaceuticals, Inc. | 1 | $127 |
| AbbVie | 6 | $116 |
| Johnson & Johnson | 5 | $106 |
| Intuitive Surgical | 1 | $82 |
| Insmed, Inc. | 2 | $60 |
| Octapharma USA, Inc. | 2 | $32 |
| Organon | 1 | $29 |
| EMD Serono, Inc. | 1 | $22 |
| Napo Pharmaceuticals Inc | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
| KCI USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,212 in reported general payments places this provider in the 70th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 71 | $227,265 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 29 | $127,635 |
| Daptomycin | 36 | $97,781 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $32,653 |
| TivicayDolutegravir Sodium | 12 | $26,914 |
| Cefepime Hcl | 12 | $3,492 |
| CeftriaxoneCeftriaxone Sodium | 46 | $1,628 |
| Rifampin | 25 | $1,339 |
| Ethambutol Hcl | 15 | $857 |
| Azithromycin | 15 | $616 |
| Cefazolin Sodium | 11 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay | $1,108 | $254,17983 claims |
| GileadBiktarvy, Stribild | $654 | $160,28840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 65 infectious disease providers in Nevada.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.